We are live on
!
Find out more
KAM
Krensavage Asset Management Portfolio holdings
AUM
$256M
1-Year Est. Return
69.63%
This Fund
S&P 500
This Quarter
Est. Return
+2.57%
1 Year Est. Return
+69.63%
3 Year Est. Return
+113.28%
5 Year Est. Return
+196.5%
10 Year Est. Return
+463.27%
AUM
$412M
AUM Growth
+$91.4M
(+28%)
Cap. Flow
+$86M
Cap. Flow
% of AUM
20.85%
Top 10 Holdings %
Top 10 Hldgs %
88.37%
Holding
18
New
2
Increased
10
Reduced
4
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
United Therapeutics
UTHR
|
+$45.7M |
| 2 |
Amgen
AMGN
|
+$31.9M |
| 3 |
McKesson
MCK
|
+$25.7M |
| 4 |
Merck
MRK
|
+$22.2M |
| 5 |
SHPG
Shire pic
SHPG
|
+$16.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SCMP
Sucampo Pharmaceuticals, Inc.
SCMP
|
+$23.4M |
| 2 |
Enanta Pharmaceuticals
ENTA
|
+$9.78M |
| 3 |
Orthofix Medical
OFIX
|
+$3.21M |
| 4 |
JNP
Juniper Pharmaceuticals, Inc. Common Stock
JNP
|
+$901K |
| 5 |
CONMED
CNMD
|
+$37.2K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
United Therapeutics
UTHR
$25.8B
| $73.5M | 17.82% |
653,787
+359,358
| +122% | +$45.7M |
|
|
2
Enanta Pharmaceuticals
ENTA
$366M
| $59.9M | 14.52% |
739,738
-127,032
| -15% | -$9.78M |
|
|
3
Amgen
AMGN
$208B
| $44.6M | 10.81% |
261,420
+173,943
| +199% | +$31.9M |
|
|
4
McKesson
MCK
$100B
| $41M | 9.96% |
291,392
+164,910
| +130% | +$25.7M |
|
5
Gilead Sciences
GILD
$162B
| $39.4M | 9.55% |
522,003
+43,950
| +9% | +$3.49M |
|
|
6
Merck
MRK
$322B
| $30.1M | 7.3% |
578,762
+411,642
| +246% | +$22.2M |
|
|
SRGA
7
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
| $20.1M | 4.87% |
145,393
+898
| +0.6% | +$122K |
|
|
IVC
8
DELISTED
Invacare Corporation
IVC
| $19.4M | 4.71% |
1,114,658
+6,888
| +0.6% | +$121K |
|
|
AVNS
9
DELISTED
Avanos Medical
AVNS
| $18.5M | 4.49% |
401,400
+6,385
| +2% | +$303K |
|
|
SHPG
10
DELISTED
Shire pic
SHPG
| $17.9M | 4.35% |
+120,000
| New | +$16.5M |
|
|
11
Orthofix Medical
OFIX
$477M
| $15.7M | 3.81% |
267,052
-57,305
| -18% | -$3.21M |
|
|
12
CONMED
CNMD
$1.39B
| $10.4M | 2.52% |
163,924
-623
| -0.4% | -$37.2K |
|
|
JNP
13
DELISTED
Juniper Pharmaceuticals, Inc. Common Stock
JNP
| $3.38M | 0.82% |
332,838
-107,264
| -24% | -$901K |
|
|
VXRT
14
DELISTED
Vaxart
VXRT
| $1.37M | 0.33% |
256,973
+1,561
| +0.6% | +$10.1K |
|
|
STRR
15
DELISTED
Star Equity Holdings
STRR
| $552K | 0.13% |
7,127
+43
| +0.6% | +$4.79K |
|
|
SCMP
16
DELISTED
Sucampo Pharmaceuticals, Inc.
SCMP
| – | – |
-1,304,376
| Closed | -$23.4M |
|
Similar funds
CIA
2
CIM
JFG
PIP
LRIC
GAMC
TIA
Krensavage Asset Management's Q1 2018 Portfolio in Review
As of Q1 2018, Krensavage Asset Management held 18 positions worth $412M, up 28% from $321M the previous quarter. Its ten largest holdings account for 88% of the portfolio.
Krensavage Asset Management deployed $86M of net new capital in Q1 2018, opening 2 new positions and adding to 10 existing holdings. Its largest new stake was Shire pic: 120,000 shares worth $17.9M.
By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 75% a quarter earlier.
On the sell side, the largest reduction was Enanta Pharmaceuticals, an estimated $9.78M trimmed.
- Krensavage Asset Management's largest Q1 2018 buy was Shire pic: 120,000 shares worth $17.9M.
- Krensavage Asset Management added most to United Therapeutics in Q1 2018, an estimated $45.7M increase.
- Krensavage Asset Management's biggest Q1 2018 reduction was Enanta Pharmaceuticals, cutting an estimated $9.78M.
- Krensavage Asset Management fully exited Sucampo Pharmaceuticals, Inc. in Q1 2018, selling an estimated $23.4M.
- Krensavage Asset Management's ten largest holdings make up 88% of its $412M portfolio in Q1 2018.
- Krensavage Asset Management opened 2 new positions and closed 2 in Q1 2018.
- Krensavage Asset Management's portfolio value rose 28% quarter-over-quarter to $412M.
Based on Krensavage Asset Management's 13F filing for Q1 2018, filed 14 May 2018.